Skip to main content

Table 2 Primary and secondary outcomes at days 7 and 14

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Outcome/time Treatment (n = 36) Control (n = 36) Absolute difference (95% CI) Effect estimate (95% CI)
Abnormal chest X-ray, No. (%)
 Day 1 11 (31%) 9 (25%) 0.06 (−0.15 to 0.26)a 1.22 (0.58 to 2.59)c
 Day 14 12 (33%) 11 (31%) 0.03 (−0.19 to 0.24)a 1.09 (0.56 to 2.14)c
Positive PCR CT ratio, No. (%)
 Day 1 36 (100%) 36 (100%) 0.00 (0.00 to 0.00)a 1.00 (1.00 to 1.00)c
 Day 7 29 (81%) 30 (83%) −0.03 (−0.21 to 0.15)a 0.97 (0.78 to 1.20)c
 Day 14 19 (53%) 20 (56%) −0.03 (−0.26 to 0.20)a 0.95 (0.62 to 1.45)c
PCR CT ratio, Mean ± SD
 Day 1 23.65 ± 7.12 22.05 ± 5.10 1.60 (−1.31 to 4.51)b   
 Day 7 25.99 ± 12.90 24.72 ± 11.17 1.27 (−4.48 to 7.03)b   
 Day 14 17.43 ± 16.82 18.51 ± 17.34 −1.09 (−9.12 to 6.95)b   
N gene, Mean ± SD
 Day 1 23.36 ± 6.20 22.42 ± 5.46 0.93 (−1.81 to 3.68)b   
 Day 7 28.62 ± 11.10 26.22 ± 10.60 2.21 (−3.04 to 7.45)b   
 Day 14 20.02 ± 17.29 19.17 ± 17.09 0.85 (−7.23 to 0.93)b   
  1. aAbsolute difference is the difference in proportions
  2. bAbsolute difference is the mean difference
  3. cEffect estimate is the risk ratios (RR)